Aarti Drugs Ltd (AARTIDRUGS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 657348,
    "name": "Aarti Drugs",
    "stock_name": "Aarti Drugs",
    "full_name": "Aarti Drugs Ltd",
    "name_url": "stocks-analysis/aarti-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "371.00",
    "chg": 3.35,
    "chgp": "0.91%",
    "dir": 1,
    "prev_price": "367.65",
    "mcapval": "3,386.12 Cr",
    "mcap": "Small Cap",
    "scripcode": 524348,
    "symbol": "AARTIDRUGS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE767A01016",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "2.58 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/aarti-drugs-657348-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3997764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_valuationdot_3997764.png",
        "date": "2026-05-19 08:01:13",
        "description": "Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-by-marketsmojo-3975745",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_mojoScore_3975745.png",
        "date": "2026-05-05 10:10:34",
        "description": "Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the most recent insights into the company’s performance and outlook."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-3960622",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AartiDrugsLtd_mojoScore_3960622.png",
        "date": "2026-04-24 10:10:31",
        "description": "Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Aarti Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-is-rated-sell-3944595",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AartiDrugsLtd_mojoScore_3944595.png",
        "date": "2026-04-13 10:10:32",
        "description": "Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Aarti Drugs Ltd Investment Rating Upgraded to Sell on Improving Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aarti-drugs-ltd-investment-rating-upgraded-to-sell-on-improving-fundamentals-3929626",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AartiDrugsLtd_mojoScore_3929626.png",
        "date": "2026-04-02 08:16:14",
        "description": "Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player."
      }
    ],
    "total": 15,
    "sid": "657348",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/aarti-drugs-657348"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "16-Jun-2026",
      "details": "Intimation of Analyst/ Institutional Meeting",
      "source": "BSE"
    },
    {
      "caption": "Transfer Of Equity Shares Of The Company To IEPF",
      "datetime": "16-Jun-2026",
      "details": "Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "05-Jun-2026",
      "details": "Intimation of Analyst/Institutional Investor meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has declared <strong>20%</strong> dividend, ex-date: 09 Feb 26",
          "dt": "2026-02-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 30 Sep 20",
          "dt": "2020-09-30",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-05-19 08:01:13

Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks.

Aarti Drugs Ltd is Rated Sell by MarketsMOJO

2026-05-05 10:10:34

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the most recent insights into the company’s performance and outlook.

Aarti Drugs Ltd is Rated Sell

2026-04-24 10:10:31

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd is Rated Sell

2026-04-13 10:10:32

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd Investment Rating Upgraded to Sell on Improving Fundamentals

2026-04-02 08:16:14

Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player.

View All News